Details of Disease

General Information of Disease (ID: DISKWK9M)

Disease Name Mesothelioma
Synonyms mesothelioma
Disease Class 2C51: Peritoneal cancer
Definition A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.
Disease Hierarchy
DIS7A27T: Mesothelial neoplasm
DISKWK9M: Mesothelioma
ICD Code
ICD-11
ICD-11: 2C51.2
ICD-10
ICD-10: C45
ICD-9
ICD-9: 163
Expand ICD-11
'2C51.2; '2C26.0; '2C53.1
Expand ICD-10
'C45
Expand ICD-9
163
Disease Identifiers
MONDO ID
MONDO_0005065
MESH ID
D008654
UMLS CUI
C0025500
MedGen ID
9975

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Intedanib DMSTA36 Approved Small molecular drug [1]
Tazemetostat DMWP1BH Approved Small molecular drug [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 19 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Galinpepimut-S DMTEQEQ Phase 3 NA [2]
NGR-TNF DM835LV Phase 3 Fusion protein [3]
Pegargiminase DMQKFWX Phase 3 Recombinant protein [1]
Anetumab ravtansine DMKFRWU Phase 2 Antibody drug conjugate [4]
BNC-105 DMJC8DR Phase 2 Small molecular drug [5]
CRS-207 DMXU5LZ Phase 2 Vaccine [2]
IPI-549 DMG5Q7F Phase 2 NA [1]
MORAb-009 DMCXNIP Phase 2 Antibody [6]
TRC102 DMPGDKG Phase 2 NA [1]
VS-6063 DMGBLI3 Phase 2 Small molecular drug [7]
Anti-mesothelin CAR transduced PBL DMXI03L Phase 1/2 CAR T Cell Therapy [8]
Anti-Mesothelin CAR-T cells DM4NMBW Phase 1/2 CAR T Cell Therapy [9]
CBP-501 DMCWVPU Phase 1/2 Small molecular drug [10]
ATA2271 DM6O0TM Phase 1 CAR T Cell Therapy [11]
CRS-207 + GVAX DMBP89G Phase 1 NA [12]
ICasp9M28z T cell DMY6V5T Phase 1 CAR T Cell Therapy [13]
LMB-100 DMXVR46 Phase 1 NA [1]
SCH-721015 DMDP6UF Phase 1 NA [14]
SEL-403 DM57JZS Phase 1 NA [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 Drug(s)
This Disease is Treated as An Indication in 1 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
DHAC DMUSNCS Discontinued in Phase 2 Small molecular drug [15]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Pemfexy DMKJ393 Application submitted NA [1]
ATA3271 DMXQVBT Preclinical CAR T Cell Therapy [16]
DP-3975 DMYH3VR Preclinical Small molecular drug [17]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 68 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CSPG4 TT7MYXI Limited Biomarker [18]
FGF18 TT6ICRA Limited Altered Expression [19]
GJA5 TTFQKZ7 Limited Altered Expression [20]
GJC1 TTEP7OC Limited Biomarker [20]
GPC3 TTJTSX4 Limited Altered Expression [21]
HOXA7 TTMRE4Q Limited Altered Expression [22]
LYN TT1RWNJ Limited Altered Expression [23]
MAP2K5 TTV3O87 Limited Biomarker [24]
MC1R TT0MV2T Limited Altered Expression [25]
MTAP TTDBX7N Limited Biomarker [26]
MTOR TTCJG29 Limited Biomarker [27]
NCR1 TTQNRJM Limited Altered Expression [28]
NF2 TTZIK7P Limited Genetic Variation [29]
PDGFD TTSN0GA Limited Biomarker [30]
SYK TT2HUPM Limited Biomarker [31]
TBXAS1 TTKNWZ4 Limited Altered Expression [32]
TPBG TT70MLA Limited Altered Expression [33]
VSIR TT51SK8 Limited Altered Expression [34]
WNT7A TT8NARC Limited Biomarker [22]
ARHGEF3 TT1R5DZ Disputed Biomarker [35]
FGF4 TTCEKVZ Disputed Biomarker [36]
TNFRSF18 TTG6LA7 Disputed Biomarker [37]
CAT TTPS279 moderate Biomarker [38]
CDH1 TTLAWO6 moderate Biomarker [39]
CDKN1B TTLGFVW moderate Biomarker [40]
CEACAM5 TTY6DTE moderate Biomarker [41]
EGR1 TTE8LGD moderate Biomarker [42]
ESR1 TTZAYWL moderate Biomarker [43]
FGF1 TTMY81X moderate Biomarker [42]
FHIT TTMS54D moderate Biomarker [44]
GSN TTUH7OM moderate Biomarker [45]
PDGFA TTSM78N moderate Biomarker [46]
PDGFC TTOABM9 moderate Biomarker [45]
PGR TTUV8G9 moderate Genetic Variation [47]
SDC2 TT5H2F0 moderate Biomarker [48]
SLC46A1 TTY8Z2E moderate Posttranslational Modification [49]
TXNRD1 TTR7UJ3 moderate Biomarker [50]
AQP1 TTSF1KH Strong Altered Expression [51]
CA9 TT2LVK8 Strong Biomarker [52]
CD274 TT8ZLTI Strong Biomarker [34]
CD46 TTMS7DF Strong Biomarker [53]
CD70 TTNCIE0 Strong Altered Expression [54]
CD74 TTCMYP9 Strong Altered Expression [55]
CEACAM3 TTPX7I5 Strong Altered Expression [56]
CLDN4 TTMTS9H Strong Biomarker [41]
CTAG1A TTE5ITK Strong Posttranslational Modification [57]
EPHB4 TTI4ZX2 Strong Biomarker [58]
FGF2 TTGKIED Strong Biomarker [19]
FOLR1 TTVC37M Strong Biomarker [59]
FOLR2 TTT54CI Strong Biomarker [59]
FOLR3 TTSM9YR Strong Altered Expression [60]
GCLM TTNFESW Strong Biomarker [61]
HTRA1 TT8POQR Strong Altered Expression [62]
IL13RA2 TTMPZ7V Strong Biomarker [63]
LSM1 TT2KHSC Strong Altered Expression [64]
MAPK7 TTU6FSC Strong Biomarker [65]
MDM2 TT9TE0O Strong Biomarker [66]
METAP2 TTZL0OI Strong Biomarker [67]
MLANA TT362RB Strong Altered Expression [68]
MUC16 TTC1PS3 Strong Biomarker [69]
PDGFB TTQA6SX Strong Altered Expression [70]
PKN1 TTSL41O Strong Biomarker [71]
SFRP4 TTX8I1Y Strong Biomarker [72]
SPP1 TT8ME6I Strong Biomarker [73]
TNFRSF8 TT2GM5R Strong Biomarker [74]
TXN TTZJ5U9 Strong Altered Expression [75]
TYMS TTP1UKZ Strong Biomarker [49]
SETD7 TTJ0FSU Definitive Biomarker [76]
------------------------------------------------------------------------------------
⏷ Show the Full List of 68 DTT(s)
This Disease Is Related to 8 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCA2 DTJ4NEG Limited Altered Expression [77]
ABCA5 DT195NK Limited Altered Expression [77]
ABCA8 DT9NXMV Limited Altered Expression [77]
SLC20A1 DTMULXV Limited Altered Expression [78]
SLC20A2 DTFD4VB Limited Biomarker [78]
SLC29A2 DTW78DQ Limited Genetic Variation [79]
SLC6A20 DT97OMP Limited Biomarker [31]
ABCB5 DTKVEXO Definitive Biomarker [80]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
AKR1C1 DE7P2FB Limited Biomarker [81]
AKR1C2 DEOY5ZM Limited Altered Expression [81]
MARS2 DEEH5Y9 Disputed Biomarker [82]
GSTM1 DEYZEJA moderate Biomarker [83]
------------------------------------------------------------------------------------
This Disease Is Related to 101 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACTR1A OT1QAU16 Limited Genetic Variation [84]
AHNAK OT6KH1WG Limited Biomarker [85]
ANXA4 OTUCRYXL Limited Biomarker [86]
APC OTKV0TIK Limited Biomarker [31]
AVEN OTGIN5YK Limited Genetic Variation [84]
BST1 OTAV5SE7 Limited Altered Expression [87]
CALB2 OTSNMCG9 Limited Biomarker [41]
CBFA2T2 OTNOIB23 Limited Altered Expression [88]
CLDN3 OT71MN9S Limited Biomarker [89]
COPA OTZ1DTXU Limited Biomarker [90]
CSRP3 OTECBJMV Limited Altered Expression [91]
EBAG9 OTTQLQCP Limited Altered Expression [92]
EFEMP2 OT0I2B4J Limited Biomarker [93]
FRZB OTTO3DPY Limited Altered Expression [94]
GABARAP OTAQUX6E Limited Genetic Variation [95]
GBP1 OTUM7RPJ Limited Biomarker [96]
HOXA1 OTMSOJ7D Limited Altered Expression [22]
HOXB4 OTH1HRW5 Limited Altered Expression [97]
HOXB9 OTMVHQOU Limited Altered Expression [22]
IL4I1 OTK54C63 Limited Biomarker [98]
KIF22 OTY6X6BL Limited Biomarker [99]
KLHL1 OTAX6SAD Limited Biomarker [100]
KLK11 OT5PKX7Y Limited Biomarker [101]
LTBP2 OTS88GSD Limited Altered Expression [102]
LTBP3 OTME98V7 Limited Altered Expression [102]
MPHOSPH6 OT6E2S48 Limited Altered Expression [103]
MPST OTCDPH5D Limited Biomarker [104]
MUC21 OTQ8GP5L Limited Biomarker [105]
OBP2A OTBIJ5TI Limited Biomarker [99]
PDZK1IP1 OTWA6M5K Limited Genetic Variation [84]
PIAS3 OT3TWH9R Limited Altered Expression [106]
PIK3R2 OTZSUQK5 Limited Altered Expression [88]
PLXNA1 OTN0BING Limited Biomarker [107]
POT1 OTNBXJCQ Limited Genetic Variation [108]
POU1F1 OTXT8A5C Limited Altered Expression [78]
PPP1R12A OT4AVU95 Limited Altered Expression [109]
PPP1R12C OT9Q86JO Limited Altered Expression [88]
PPP1R13B OTC88VQO Limited Altered Expression [88]
PPRC1 OT6GB3WR Limited Altered Expression [110]
PRB2 OTAD4JZ0 Limited Biomarker [111]
PROCR OTRHED17 Limited Biomarker [112]
PSD4 OTEFB87Z Limited Biomarker [113]
RAN OT2TER5M Limited Biomarker [114]
REV3L OT0OP8EJ Limited Biomarker [115]
SETDB1 OTWVUA1B Limited Genetic Variation [116]
SLC7A14 OT07YJW4 Limited Genetic Variation [117]
SYCE1L OTXU44F3 Limited Biomarker [100]
TCN2 OT41D0L3 Limited Genetic Variation [118]
TRIP6 OTIPA4ZR Limited Biomarker [93]
ASXL2 OTNG4E2M Disputed Altered Expression [119]
KIF25 OTQ3VJ09 Disputed Genetic Variation [120]
NSG2 OTJ0NSPL Disputed Biomarker [121]
TLE1 OT50MRZ1 Disputed Biomarker [122]
TNFSF18 OT3ANRX1 Disputed Biomarker [123]
EID1 OT3OI5H4 moderate Biomarker [45]
JMJD6 OTILR7E4 moderate Biomarker [124]
MYO18B OTGYY4NK moderate Altered Expression [125]
NME2 OTCYGLHV moderate Biomarker [45]
PPP1R14A OTQODWZB moderate Biomarker [126]
SCARA3 OT46I38Y moderate Altered Expression [127]
SELENOF OT2JFB3S moderate Altered Expression [128]
ACACA OT5CQPZY Strong Altered Expression [78]
ASS1 OT4ZMG0Q Strong Biomarker [129]
ATP6V1E1 OT76J5R9 Strong Biomarker [130]
BMS1 OTEGQ8ZO Strong Altered Expression [78]
CEACAM7 OTKFDTZY Strong Altered Expression [56]
CTAG1B OTIQGW6U Strong Posttranslational Modification [57]
CUL4A OTTBV70J Strong Altered Expression [131]
DCTN6 OTI8PIN9 Strong Biomarker [132]
DIO2 OTGPNSLH Strong Biomarker [133]
DVL3 OTPRROHJ Strong Altered Expression [134]
EIF4A2 OT08H03R Strong Biomarker [135]
EIF4G1 OT2CF1E6 Strong Biomarker [135]
ESCO1 OTZ9P12A Strong Posttranslational Modification [57]
ETFA OTXX61VZ Strong Biomarker [136]
GDF10 OTEVXGJ7 Strong Biomarker [137]
GPC1 OTQKRSSV Strong Biomarker [138]
HAPLN1 OTXWR9TJ Strong Altered Expression [139]
ITLN1 OT7ZLJVV Strong Biomarker [140]
KRT5 OTVGI9HT Strong Biomarker [43]
LIMS2 OTZ7IIPM Strong Altered Expression [141]
LIMS3 OTTMS7V8 Strong Altered Expression [141]
LRRN4 OTC2T1MP Strong Biomarker [142]
MARCKSL1 OT13J2FM Strong Altered Expression [143]
MINDY4 OTBZ2SZB Strong Altered Expression [51]
NAPSA OT6F8IAL Strong Biomarker [41]
NKX2-1 OTCMEJTA Strong Biomarker [41]
PAX8 OTRPD9MI Strong Genetic Variation [47]
PDPN OTBUV19I Strong Altered Expression [144]
PROK1 OT8S7RUG Strong Biomarker [71]
PSG2 OT2EIXAI Strong Altered Expression [56]
PSMD8 OTY6X27P Strong Biomarker [130]
PUF60 OTG90DYF Strong Therapeutic [145]
RBL2 OTBQSOE6 Strong Altered Expression [146]
THY1 OTVONVTB Strong Altered Expression [147]
TICAM2 OTK7GIJ5 Strong Biomarker [132]
TM7SF2 OTILU5S7 Strong Altered Expression [148]
TNXB OTVBWAV5 Strong Biomarker [149]
TTF1 OT4K90WD Strong Biomarker [41]
PCGF5 OTDF5C72 Definitive Biomarker [76]
TRAF7 OTW8Q5TF Definitive Genetic Variation [150]
------------------------------------------------------------------------------------
⏷ Show the Full List of 101 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01098266) NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM). U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021025)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7750).
7 ClinicalTrials.gov (NCT01870609) Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
9 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
10 ClinicalTrials.gov (NCT00700336) Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II). U.S. National Institutes of Health.
11 Clinical pipeline report, company report or official report of Atara Biotherapeutics.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
14 ClinicalTrials.gov (NCT01162785) Phase IB Intravesical Administration of SCH 721015. U.S. National Institutes of Health.
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000908)
16 Clinical pipeline report, company report or official report of Atara Biotherapeutics.
17 AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
18 Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.Front Immunol. 2018 Jan 10;8:1911. doi: 10.3389/fimmu.2017.01911. eCollection 2017.
19 Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.
20 Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells.Carcinogenesis. 1994 Nov;15(11):2673-5. doi: 10.1093/carcin/15.11.2673.
21 Glypican-3 expression is silenced in human breast cancer.Oncogene. 2001 Nov 1;20(50):7408-12. doi: 10.1038/sj.onc.1204925.
22 Altered HOX and WNT7A expression in human lung cancer.Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12776-81. doi: 10.1073/pnas.97.23.12776.
23 Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.Carcinogenesis. 2012 May;33(5):969-75. doi: 10.1093/carcin/bgs109. Epub 2012 Feb 21.
24 HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.Am J Respir Cell Mol Biol. 2008 Feb;38(2):209-17. doi: 10.1165/rcmb.2007-0206OC. Epub 2007 Sep 13.
25 Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma.J Leukoc Biol. 2004 Feb;75(2):253-9. doi: 10.1189/jlb.0603264. Epub 2003 Oct 23.
26 Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations.Mod Pathol. 2020 Feb;33(2):312-318. doi: 10.1038/s41379-019-0411-9. Epub 2019 Nov 4.
27 Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.J Thorac Oncol. 2011 May;6(5):852-63. doi: 10.1097/JTO.0b013e31820e1a25.
28 Accelerated cell cycle progression of human regulatory Tcell-like cell line caused by continuous exposure to asbestos fibers.Int J Oncol. 2017 Jan;50(1):66-74. doi: 10.3892/ijo.2016.3776. Epub 2016 Nov 22.
29 Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.Mod Pathol. 2020 Feb;33(2):235-244. doi: 10.1038/s41379-019-0309-6. Epub 2019 Jun 23.
30 Mesothelioma cell proliferation through autocrine activation of PDGF- receptor.Cell Physiol Biochem. 2012;29(5-6):667-74. doi: 10.1159/000176386. Epub 2012 May 11.
31 DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer. 2007 Nov;58(2):220-30.
32 Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.Cancer Sci. 2015 Oct;106(10):1296-302. doi: 10.1111/cas.12752. Epub 2015 Sep 19.
33 Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.J Thorac Oncol. 2018 Oct;13(10):1577-1587. doi: 10.1016/j.jtho.2018.06.008. Epub 2018 Jun 27.
34 Expression of V-set immunoregulatory receptor in malignant mesothelioma.Mod Pathol. 2020 Feb;33(2):263-270. doi: 10.1038/s41379-019-0328-3. Epub 2019 Jul 30.
35 Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane.Free Radic Biol Med. 2018 Feb 1;115:266-277. doi: 10.1016/j.freeradbiomed.2017.12.008. Epub 2017 Dec 9.
36 Selective Uptake Into Drug Resistant Mammalian Cancer by Cell Penetrating Peptide-Mediated Delivery.Bioconjug Chem. 2018 Oct 17;29(10):3273-3284. doi: 10.1021/acs.bioconjchem.8b00429. Epub 2018 Oct 8.
37 Combination immune checkpoint blockade as an effective therapy for mesothelioma.Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111. eCollection 2018.
38 Expression and prognostic significance of catalase in malignant mesothelioma.Cancer. 2001 Apr 1;91(7):1349-57. doi: 10.1002/1097-0142(20010401)91:7<1349::aid-cncr1138>3.0.co;2-d.
39 Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.Lung Cancer. 2005 Feb;47(2):193-204. doi: 10.1016/j.lungcan.2004.08.003.
40 Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.J Egypt Natl Canc Inst. 2006 Dec;18(4):303-10.
41 Biomarkers in the diagnosis of pleural diseases: a 2018 update.Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808660. doi: 10.1177/1753466618808660.
42 Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress.J Biol Chem. 2005 Jul 8;280(27):25369-76. doi: 10.1074/jbc.M414498200. Epub 2005 May 5.
43 Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor in high-grade serous ovarian carcinoma.Hum Pathol. 2017 Sep;67:30-36. doi: 10.1016/j.humpath.2017.03.020. Epub 2017 Apr 13.
44 Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma.Pathology. 2008 Jan;40(1):42-5. doi: 10.1080/00313020701716383.
45 Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.Am J Pathol. 2005 Jun;166(6):1827-40. doi: 10.1016/S0002-9440(10)62492-3.
46 Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo.Am J Respir Cell Mol Biol. 2001 Jun;24(6):694-702. doi: 10.1165/ajrcmb.24.6.4334.
47 Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.Arch Pathol Lab Med. 2018 Feb;142(2):236-242. doi: 10.5858/arpa.2017-0092-OA. Epub 2017 Oct 19.
48 Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.J Clin Pathol. 2019 Aug;72(8):529-535. doi: 10.1136/jclinpath-2018-205650. Epub 2019 Apr 26.
49 Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol. 2017 Nov 1;28(11):2725-2732.
50 Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells.Differentiation. 2007 Feb;75(2):123-32. doi: 10.1111/j.1432-0436.2006.00121.x.
51 Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.Cytopathology. 2018 Oct;29(5):455-460. doi: 10.1111/cyt.12583. Epub 2018 Jul 23.
52 Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.Neoplasma. 2014;61(2):161-9. doi: 10.4149/neo_2014_031.
53 Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma.Oncotarget. 2017 Jun 27;8(38):63096-63109. doi: 10.18632/oncotarget.18656. eCollection 2017 Sep 8.
54 CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.J Pathol. 2020 Feb;250(2):205-216. doi: 10.1002/path.5361. Epub 2019 Dec 3.
55 Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.Oncotarget. 2016 Mar 8;7(10):11512-25. doi: 10.18632/oncotarget.7314.
56 Are oestrogens and genetic predisposition etiologic factors in the development of clear cell carcinoma of the peritoneum?.Med Hypotheses. 2013 Feb;80(2):167-71. doi: 10.1016/j.mehy.2012.11.021. Epub 2012 Dec 21.
57 HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression.Mol Oncol. 2013 Jun;7(3):452-63. doi: 10.1016/j.molonc.2012.11.004. Epub 2012 Dec 21.
58 EphB4: A promising target for upper aerodigestive malignancies.Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137. doi: 10.1016/j.bbcan.2018.01.003. Epub 2018 Jan 31.
59 The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.Br J Cancer. 2010 Feb 2;102(3):553-60. doi: 10.1038/sj.bjc.6605501. Epub 2010 Jan 5.
60 Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous... Hum Pathol. 2009 Oct;40(10):1453-60.
61 Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines.Int J Cancer. 1998 Mar 2;75(5):757-61. doi: 10.1002/(sici)1097-0215(19980302)75:5<757::aid-ijc15>3.0.co;2-3.
62 Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.Front Biosci (Elite Ed). 2013 Jun 1;5(3):974-81. doi: 10.2741/e677.
63 Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.Clin Cancer Res. 2011 May 1;17(9):2819-29. doi: 10.1158/1078-0432.CCR-10-2986. Epub 2011 Feb 28.
64 CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes.Am J Respir Cell Mol Biol. 2008 Jun;38(6):671-8. doi: 10.1165/rcmb.2007-0205OC. Epub 2008 Jan 24.
65 Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.
66 Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.J Oncol. 2018 Jul 17;2018:1986982. doi: 10.1155/2018/1986982. eCollection 2018.
67 High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts.Lab Invest. 2002 Jul;82(7):893-901. doi: 10.1097/01.lab.0000020419.25365.c4.
68 Melan A (A103) is not a marker of mesothelioma.Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):181-4. doi: 10.1097/PAI.0b013e31825e0013.
69 CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Cancer Biol Ther. 2018 Jul 3;19(7):622-630. doi: 10.1080/15384047.2018.1449614. Epub 2018 Apr 25.
70 Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression.Am J Respir Cell Mol Biol. 1993 Feb;8(2):214-21. doi: 10.1165/ajrcmb/8.2.214.
71 PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.
72 The Wnt regulator SFRP4 inhibits mesothelioma cell proliferation, migration, and antagonizes Wnt3a via its netrin-like domain.Int J Oncol. 2017 Jul;51(1):362-368. doi: 10.3892/ijo.2017.4011. Epub 2017 May 18.
73 Chlamydia trachomatis induces an upregulation of molecular biomarkers podoplanin, Wilms' tumour gene 1, osteopontin and inflammatory cytokines in human mesothelial cells.Microbiology (Reading). 2017 May;163(5):654-663. doi: 10.1099/mic.0.000465. Epub 2017 May 24.
74 A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.Invest New Drugs. 2019 Aug;37(4):738-747. doi: 10.1007/s10637-019-00768-6. Epub 2019 Apr 16.
75 The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid.Int J Oncol. 2016 May;48(5):2197-204. doi: 10.3892/ijo.2016.3402. Epub 2016 Feb 19.
76 Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.Mod Pathol. 2020 Feb;33(2):217-227. doi: 10.1038/s41379-019-0371-0. Epub 2019 Sep 30.
77 Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.Mol Cancer. 2010 Dec 15;9:314. doi: 10.1186/1476-4598-9-314.
78 Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.Cancer Gene Ther. 2013 Dec;20(12):671-7. doi: 10.1038/cgt.2013.67. Epub 2013 Nov 8.
79 Regional assignment of seven loci to 12p13.2-pter by PCR analysis of somatic cell hybrids containing the der(12) or the der(X) chromosome from a mesothelioma showing t(X;12)(q22;p13).Genomics. 1994 Mar 1;20(1):119-21. doi: 10.1006/geno.1994.1136.
80 Wnt/IL-1/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.Int J Cancer. 2020 Jan 1;146(1):192-207. doi: 10.1002/ijc.32419. Epub 2019 Jun 4.
81 Resistance to platinum-based chemotherapy in lung cancer cell lines.Cancer Chemother Pharmacol. 2010 Nov;66(6):1103-11. doi: 10.1007/s00280-010-1268-2. Epub 2010 Feb 21.
82 Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2).Trials. 2019 Oct 18;20(1):598. doi: 10.1186/s13063-019-3692-x.
83 Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma.Int J Cancer. 2007 Jun 15;120(12):2739-43. doi: 10.1002/ijc.22590.
84 Transcriptome sequencing of malignant pleural mesothelioma tumors.Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3521-6. doi: 10.1073/pnas.0712399105. Epub 2008 Feb 26.
85 AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.Int J Oncol. 2014 Feb;44(2):530-8. doi: 10.3892/ijo.2013.2183. Epub 2013 Nov 20.
86 Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.Biochem Biophys Res Commun. 2012 Apr 27;421(1):140-4. doi: 10.1016/j.bbrc.2012.03.144. Epub 2012 Apr 4.
87 Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.Oncotarget. 2018 Apr 27;9(32):22785-22801. doi: 10.18632/oncotarget.25237. eCollection 2018 Apr 27.
88 Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir.Toxicol In Vitro. 2017 Jun;41:49-55. doi: 10.1016/j.tiv.2017.02.008. Epub 2017 Feb 20.
89 Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.
90 Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.Genomics. 2010 Apr;95(4):210-6. doi: 10.1016/j.ygeno.2010.02.002. Epub 2010 Feb 11.
91 Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.Gene Ther. 1997 Apr;4(4):280-7. doi: 10.1038/sj.gt.3300385.
92 Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.Oncol Rep. 2005 Aug;14(2):357-62.
93 Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.Gene. 2013 Mar 15;517(1):99-105. doi: 10.1016/j.gene.2012.12.075. Epub 2013 Jan 9.
94 Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.Oncogene. 2004 Aug 26;23(39):6672-6. doi: 10.1038/sj.onc.1207881.
95 Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma.Cancer Sci. 2011 Mar;102(3):648-55. doi: 10.1111/j.1349-7006.2010.01827.x. Epub 2011 Jan 18.
96 Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643.
97 HOX transcription factors are potential targets and markers in malignant mesothelioma.BMC Cancer. 2016 Feb 11;16:85. doi: 10.1186/s12885-016-2106-7.
98 IL4I1: an inhibitor of the CD8?antitumor T-cell response in vivo.Eur J Immunol. 2011 Jun;41(6):1629-38. doi: 10.1002/eji.201041119. Epub 2011 May 13.
99 A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.Oncogene. 2010 Feb 25;29(8):1145-54. doi: 10.1038/onc.2009.415. Epub 2009 Nov 23.
100 The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma.Ann Oncol. 2001 Sep;12(9):1239-45. doi: 10.1023/a:1012292230480.
101 Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.Cancer Res. 2006 Mar 15;66(6):2970-9. doi: 10.1158/0008-5472.CAN-05-3907.
102 Latent TGF- binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor- activity in malignant mesothelioma.Hum Pathol. 2011 Feb;42(2):269-78. doi: 10.1016/j.humpath.2010.07.005. Epub 2010 Nov 24.
103 MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9. doi: 10.1165/rcmb.2009-0060OC. Epub 2009 Jun 5.
104 CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.Oncol Rep. 2013 Jan;29(1):21-8. doi: 10.3892/or.2012.2116. Epub 2012 Oct 31.
105 Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.Histopathology. 2019 Mar;74(4):545-554. doi: 10.1111/his.13775. Epub 2019 Jan 15.
106 Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.Clin Cancer Res. 2014 Oct 1;20(19):5124-32. doi: 10.1158/1078-0432.CCR-14-1233. Epub 2014 Aug 14.
107 The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.Cancer Res. 2009 Feb 15;69(4):1485-93. doi: 10.1158/0008-5472.CAN-08-3659. Epub 2009 Jan 27.
108 CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.Cancer Lett. 2016 Aug 10;378(2):120-30. doi: 10.1016/j.canlet.2016.05.011. Epub 2016 May 12.
109 Identification of genes involved in human mesothelial cancer progression using a modified differential display technique.Cancer Lett. 1998 Jan 16;123(1):7-14. doi: 10.1016/s0304-3835(97)00317-0.
110 Polycomb repressor complex-2 is a novel target for mesothelioma therapy.Clin Cancer Res. 2012 Jan 1;18(1):77-90. doi: 10.1158/1078-0432.CCR-11-0962. Epub 2011 Oct 25.
111 The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas.Nat Med. 1997 Aug;3(8):913-6. doi: 10.1038/nm0897-913.
112 Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.Cancer Res. 2013 Jul 1;73(13):3963-73. doi: 10.1158/0008-5472.CAN-12-1690. Epub 2013 Mar 28.
113 The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.Stem Cell Res Ther. 2017 May 25;8(1):119. doi: 10.1186/s13287-017-0573-7.
114 Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.Lung Cancer. 2010 Jan;67(1):57-68. doi: 10.1016/j.lungcan.2009.03.016.
115 Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.Neoplasia. 2011 Oct;13(10):961-70. doi: 10.1593/neo.11828.
116 Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.Oncotarget. 2016 Feb 16;7(7):8321-31. doi: 10.18632/oncotarget.7032.
117 Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.PLoS One. 2013 Apr 23;8(4):e61253. doi: 10.1371/journal.pone.0061253. Print 2013.
118 Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort.J Thorac Oncol. 2009 Oct;4(10):1259-63. doi: 10.1097/JTO.0b013e3181aba6bd.
119 Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.Nat Commun. 2018 Oct 22;9(1):4385. doi: 10.1038/s41467-018-06854-2.
120 Genome Evolution Analysis of Recurrent Testicular Malignant Mesothelioma by Whole-Genome Sequencing.Cell Physiol Biochem. 2018;45(1):163-174. doi: 10.1159/000486355. Epub 2018 Jan 15.
121 Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).Curr Biol. 2017 Nov 6;27(21):3302-3314.e6. doi: 10.1016/j.cub.2017.09.007.
122 Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data.Pathology. 2018 Oct;50(6):629-634. doi: 10.1016/j.pathol.2018.06.001. Epub 2018 Aug 28.
123 Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).Lung Cancer. 2019 Jan;127:138-145. doi: 10.1016/j.lungcan.2018.11.034. Epub 2018 Nov 29.
124 Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.Front Genet. 2018 Dec 18;9:675. doi: 10.3389/fgene.2018.00675. eCollection 2018.
125 Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.Oncol Res. 2006;16(5):235-43. doi: 10.3727/000000006783981062.
126 Functional inactivation of NF2/merlin in human mesothelioma.Lung Cancer. 2009 May;64(2):140-7. doi: 10.1016/j.lungcan.2008.08.014. Epub 2008 Oct 4.
127 SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.Hum Pathol. 2012 May;43(5):669-74. doi: 10.1016/j.humpath.2011.06.003. Epub 2011 Aug 19.
128 Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene. 2004 Jun 24;23(29):5032-40. doi: 10.1038/sj.onc.1207683.
129 Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.
130 Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cells.Oncotarget. 2017 Oct 16;8(55):94711-94725. doi: 10.18632/oncotarget.21885. eCollection 2017 Nov 7.
131 Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.J Cell Mol Med. 2015 Oct;19(10):2385-96. doi: 10.1111/jcmm.12620. Epub 2015 Jul 27.
132 miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma.Front Oncol. 2018 Oct 22;8:446. doi: 10.3389/fonc.2018.00446. eCollection 2018.
133 The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem. 2001 Aug 10;276(32):30183-7. doi: 10.1074/jbc.C100325200. Epub 2001 Jun 25.
134 Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.Oncol Lett. 2018 Jan;15(1):833-838. doi: 10.3892/ol.2017.7382. Epub 2017 Nov 9.
135 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.Invest New Drugs. 2018 Apr;36(2):217-229. doi: 10.1007/s10637-017-0535-z. Epub 2017 Nov 8.
136 Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.Diagn Cytopathol. 2016 Jul;44(7):591-8. doi: 10.1002/dc.23490. Epub 2016 Apr 15.
137 The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep. 2008 Nov;20(5):1265-8.
138 Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.Mod Pathol. 2018 Sep;31(9):1400-1403. doi: 10.1038/s41379-018-0066-y. Epub 2018 May 21.
139 Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.Clin Cancer Res. 2009 Apr 15;15(8):2602-11. doi: 10.1158/1078-0432.CCR-08-2755. Epub 2009 Apr 7.
140 Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma.Am J Surg Pathol. 2017 Aug;41(8):1045-1052. doi: 10.1097/PAS.0000000000000852.
141 PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.Cytopathology. 2011 Feb;22(1):22-9. doi: 10.1111/j.1365-2303.2010.00757.x.
142 LRRN4 and UPK3B are markers of primary mesothelial cells.PLoS One. 2011;6(10):e25391. doi: 10.1371/journal.pone.0025391. Epub 2011 Oct 3.
143 Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.Clin Cancer Res. 2001 Oct;7(10):3199-205.
144 Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.Cancer Sci. 2019 May;110(5):1653-1664. doi: 10.1111/cas.13979. Epub 2019 Mar 12.
145 Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci. 2011 Jul;102(7):1366-73. doi: 10.1111/j.1349-7006.2011.01931.x. Epub 2011 May 9.
146 RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.Oncogene. 2018 Jul;37(27):3657-3671. doi: 10.1038/s41388-018-0214-3. Epub 2018 Apr 2.
147 Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.Front Oncol. 2018 Feb 23;8:40. doi: 10.3389/fonc.2018.00040. eCollection 2018.
148 Role of angiopoietins in mesothelioma progression.Cytokine. 2019 Jun;118:99-106. doi: 10.1016/j.cyto.2018.08.006. Epub 2018 Sep 7.
149 Tenascin-X is a novel diagnostic marker of malignant mesothelioma.Am J Surg Pathol. 2009 Nov;33(11):1673-82. doi: 10.1097/PAS.0b013e3181b6bde3.
150 Molecular characterization of localized pleural mesothelioma.Mod Pathol. 2020 Feb;33(2):271-280. doi: 10.1038/s41379-019-0330-9. Epub 2019 Aug 1.